No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.
Title | No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial. |
Publication Type | Journal Article |
Year of Publication | 2009 |
Authors | Anastasilakis, A. D., Goulis D. G., Polyzos S. A., Gerou S., Ballaouri I., Efstathiadou Z., Kita M., & Avramidis A. |
Journal | Clin Endocrinol (Oxf) |
Volume | 70 |
Issue | 4 |
Pagination | 522-6 |
Date Published | 2009 Apr |
ISSN | 1365-2265 |
Keywords | Aged, Alkaline Phosphatase, Bone and Bones, Bone Density Conservation Agents, Calcium, Collagen Type I, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Humans, Middle Aged, Organometallic Compounds, Osteoporosis, Postmenopausal, Peptides, Teriparatide, Thiophenes, Treatment Outcome, Vitamin D |
Abstract | UNLABELLED: Objective To evaluate the effect of strontium ranelate (SR) on bone turnover markers in women with established osteoporosis previously treated with teriparatide (TPTD--recombinant human PTH 1-34). DESIGN PATIENTS: Twenty-two postmenopausal Caucasian women (aged 65.7 +/- 1.7 years) with established osteoporosis previously treated with TPTD 20 microg daily for 18 months were randomly assigned to receive either SR (SR group, n = 11) or calcium and vitamin D (control group, n = 11).MEASUREMENTS: Blood samples for serum N-terminal propeptide of type 1 collagen (P1NP), C-terminal telopeptide of type 1 collagen (CTx) and total alkaline phosphatase (ALP) were obtained from all women before (pre-TPTD) and after (post-TPTD) TPTD administration, as well as 6 months after SR or calcium/vitamin D administration (post-SR/Ca).RESULTS: Serum P1NP, CTx and total ALP increased significantly after TPTD treatment and decreased at the end of the study in both SR and control groups, with no difference between them.CONCLUSIONS: SR following TPTD administration acts predominantly as an antiresorptive agent with no evidence of additional osteoanabolic action. In this setting, SR is not more effective than Ca/vitamin D as far as bone turnover markers are concerned. |
DOI | 10.1111/j.1365-2265.2008.03342.x |
Alternate Journal | Clin. Endocrinol. (Oxf) |
PubMed ID | 18625000 |